Journal
MOLECULAR IMAGING AND BIOLOGY
Volume 11, Issue 2, Pages 79-87Publisher
SPRINGER
DOI: 10.1007/s11307-008-0148-1
Keywords
HB22.7; CD22; Non-Hodgkin's lymphoma; PET; Cu-64
Funding
- NCI [R24 CA86307]
- NIH, NCI [R33 CA89706]
- University of California Cancer Research Program
- VA Merit grants [1337754, 7855423]
- Small Animal Resource Program [R24 CA110804]
- Leukemia and Lymphoma Society Translational Research Award
- Schwedler Foundation and the deLeuze Endowment for the non-toxic cure of lymphoma
- [00-00764V-0133]
Ask authors/readers for more resources
Purpose: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of Cu-64-DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP),and subcutaneously (SQ). Procedures: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with Cu-64-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of Cu-64 were performed to determine the pharmacokinetics and clearance of Cu-64-DOTA-HB22.7. Results: Cu-64-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that Cu-64-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. Conclusions: These findings establish Cu-64-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available